News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY) Melanoma Drug Cuts Risk Of Death By 63 Percent; Bests Bristol-Myers Squibb Company (BMY) In Study


6/6/2011 8:15:54 AM

Advanced melanoma patients treated with an experimental pill developed by Roche and Daiichi Sankyo were 63 percent less likely to die than patients given chemotherapy, according to a new trial. The drug, vemurafenib, is designed for use in patients with tumors that have a mutation in a gene known as BRAF. About half of all melanomas -- the deadliest form of skin cancer -- have the genetic aberration.

Read at Reuters
Read at Bloomberg
Read at Minyanville
Read at BusinessWeek

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES